Monitoring compliance with standards of care for chronic diseases using healthcare administrative databases in Italy: Strengths and limitations

PLoS One. 2017 Dec 12;12(12):e0188377. doi: 10.1371/journal.pone.0188377. eCollection 2017.

Abstract

Background: A recent comprehensive report on healthcare quality in Italy published by the Organization of Economic Co-operation and Development (OECD) recommended that regular monitoring of quality of primary care by means of compliance with standards of care for chronic diseases is performed. A previous ecological study demonstrated that compliance with standards of care could be reliably estimated on regional level using administrative databases. This study compares estimates based on administrative data with estimates based on GP records for the same persons, to understand whether ecological fallacy played a role in the results of the previous study.

Methods: We compared estimates of compliance with diagnostic and therapeutic standards of care for type 2 diabetes (T2DM), hypertension and ischaemic heart disease (IHD) from administrative data (IAD) with estimates from medical records (MR) for the same persons registered with 24 GP's in 2012. Data were linked at an individual level.

Results: 32,688 persons entered the study, 12,673 having at least one of the three diseases according to at least one data source. Patients not detected by IAD were many, for all three conditions: adding MR increased the number of cases of T2DM, hypertension, and IHD by +40%, +42%, and +104%, respectively. IAD had imperfect sensitivity in detecting population compliance with therapies (adding MR increased the estimate, from +11.5% for statins to +14.7% for antithrombotics), and, more substantially, with diagnostic recommendations (adding MR increased the estimate, from +23.7% in glycated hemoglobin tests, to +50.5% in electrocardiogram). Patients not detected by IAD were less compliant with respect to those that IAD correctly identified (from -4.8 percentage points in proportion of IHD patients compliant with a yearly glycated hemoglobin test, to -40.1 points in the proportion of T2DM patients compliant with the same recommendation). IAD overestimated indicators of compliance with therapeutic standards (significant differences ranged from 3.3. to 3.6 percentage points) and underestimated indicators of compliance with diagnostic standards (significant differences ranged from -2.3 to -14.1 percentage points).

Conclusion: IAD overestimated the percentage of patients compliant with therapeutic standards by less than 6 percentage points, and underestimated the percentage of patients compliant with diagnostic standards by a maximum of 14 percentage points. Therefore, both discussions at local level between GP's and local health unit managers and discussions at central level between national and regional policy makers can be informed by indicators of compliance estimated by IAD, which, based on those results, have the ability of signalling critical or excellent clusters. However, this study found that estimates are partly flawed, because a high number of patients with chronic diseases are not detected by IAD, patients detected are not representative of the whole population of patients, and some categories of diagnostic tests are markedly underrecorded in IAD (up to 50% in the case of electrocardiograms). Those results call to caution when interpreting IAD estimates. Audits based on medical records, on the local level, and an interpretation taking into account information external to IAD, on the central level, are needed to assess a more comprehensive compliance with standards.

MeSH terms

  • Chronic Disease / therapy*
  • Diabetes Mellitus, Type 2 / therapy
  • Female
  • Guideline Adherence*
  • Humans
  • Hypertension / therapy
  • Italy
  • Male
  • Myocardial Ischemia / therapy

Grants and funding

This study was funded by the project named “Integrazione dei contenuti informativi per la gestione sul territorio di pazienti con patologie complesse o con patologie croniche”, short name MATRICE, funded by the Italian Ministry of Health to M Bellentani. The funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. I Cricelli, A Pasqua and F Lapi are employed by Genomedics, which is a commercial company, and M J Schuemie is employed by Janssen Research and Development LLC, which is a commercial company. Genomedics and Janssen Research and Development LLC provided support in the form of salaries for authors I Cricelli, A Pasqua, F Lapi and M J Schuemie, respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.